Targeted therapy in patient with PIK3CA related overgrowth syndrome.
CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome) is a genetic disorder that results from somatic, mosaic gain-of-function mutations of the PIK3CA gene, and belongs to the spectrum of PIK3CA-related overgrowth syndromes (PROS). This rare condition has no specific treatment and a poor survival rate. On the basis of studies in postnatal mouse models, BYL719, an inhibitor of PIK3CA, was used to treat nineteen patients with PROS. The drug improved the disease symptoms in all patients. The treatment was not associated with any substantial side effects. This study provides the first direct evidence supporting PIK3CA inhibition as a promising therapeutic strategy in patients with PROS.
Elisa Araldi, chair of the Life Science Switzerland (LS2) annual meeting PIs of Tomorrow (PIOT) session, CH
If you want to start an academic career in Switzerland, the LS2 PIOT session (Zurich February 13-14, 2020) is a great opportunity to showcase your past work and future project plans, and to get valuable feedback on your job interview talk from a knowledgeable jury of professors. - The PIOT session is one of the most attended session of the LS2 meeting, and most of the past winners now hold positions as group leaders!
by Sabine Werner (Professor at the Institute for Molecular Health Sciences, ETH Zürich, & member of the foundation council and executive committee of the SNF, CH)
co-leads: Alexandra Zingg (Project Manager EU GrantsAccess office ETHZ, CH) & Joao Matos (Assistant Professor ETHZ, CH)
What is the best path to transition from a postdoc to become an independent researcher? What are the different funding agencies that one can apply to? What is the best moment to start applying for funding? In this workshop we will try to answer those questions and get the different points of view of people that have successfully perform this transition and helped others to achieve it. Join this session if you are curious about what does it take to successfully bring your own research idea to the next level.
by Verity Elston (Head of Careers Advice for the Graduate Campus UNIL & Director of Portfolio Formation, Lausanne, CH)
With so few tenure track academic positions on the market, many postdoctoral researchers consider other career paths. Join this session if you are curious about how one makes the transition from an academic position into a career outside of academia. We will explore what resources and strategies are available to you to support this transition.
This session is limited to 25 participants. Registration is on a first come, first serve basis.
Please no photography or posting of unpublished content on social media unless you obtain the explicit permission of the presenter.
by Wen Hwa Lee (Chief Executive Officer at Action Against AMD & Programme Director of the Oxford Martin Programme on Affordable Medicines)
Markus Köster (Director, Corporate Department Research Coordination at Boehringer Ingelheim, DE)
Leila Alexander (COO, Personalized Health Informatics Group at the Swiss Institute of Bioinformatics, CH)
Open Science Culture – Science for all, by all
Most of the biggest challenges we face today can’t be solved by isolated groups of very specialised scientists and their knowledge. It is thus imperative that we start exploring how to bring together the many experts to create knowledge which is much bigger than the sum of its parts – the path to breakthrough innovation.
One of the most effective way to achieve this next level of hyper-connection is to start sharing real, high-quality research tools and platforms, where anyone can get free or equitable access to co-create with colleagues from all disciplines and sectors.
We will be running three parallel workshops (limited seats!) using Open Science resources which are available right now, including drug discovery compounds, datasets for AI, data sciences and personalised medicine in UK and Switzerland.
Translating cellular therapies from the bench to the bedside.
In this talk it will be exemplified how crucial preclinical laboratory studies were and continue to be for the improvement of existing hematopoietic cell therapies and the development of innovative strategies such as chimeric antigen-receptor T cell therapies. Cellular therapies are one prime example of true translational innovation reaching and shaping today’s everyday care.
Best Poster and Science Pitch will receive a prize sponsored by Roche and ETH PACE respectively.
Open and reproducible Science - the ScienceMatters way.
There is a serious crisis in current models of science publishing: Irreproducibility, non-communication and blocked access of scientific data. One of the important reasons for this crisis is the pressure and demand for full story-based, positive scientific studies to be considered for publication in most of the journals. The agony and the anxiety to get the studies in limited space in these journals combined with the unfair incentives of a “Publish or Perish” culture breed dishonesty that gives rise to irreproducibility in science. During this tortuous process, many scientific observations remain unpublished either because of the inability to develop them into the “stories” including negative data, confirmatory data or observations that are not “sexy” enough. Estimates are that less than 1% of researchers publish more than one paper a year. This suggests that most of the scientific observations made with taxpayers’ funds are never communicated to find place in scholarly space. We would like to change this fundamentally.
We have created ScienceMatters (www.sciencematters.io) is the first platform for scientists to publish single observations and not fully developed stories. By eliminating the need to tell full stories, and favoring simple data-based observations over story-telling, we eliminate the current pressure to tell sexy stories. Scientists can publish single and robustly validated observations, be it orphan, negative, confirmatory, contradicting after the observations are vetted through triple-blind peer-review and all the peer review reports are published along with the papers. This also reduces the negative incentives associated with publishing in high-impact journals, namely to come up with data that must fit the big storyline, since it is this narrative pressure that in some unfortunate cases can lead to fraudulence. Therefore, ScienceMatters brings honesty and speed to scientific publishing and helps the science community to produce robust and better results. The platform is open access and allows scientists to get the unique opportunity to publish peer-reviewed single observations with the integration of cutting-edge social media features, thus engaging the community to provide post-publication review both by the experts and other scientists/readers. The platform has the possibility of being a one-stop source for rapid dissemination of honest and scientifically valid observations or data on replication, thereby enabling the natural emergence of the honest scientific narrative as opposed to the pruned narrative of data, as it is done currently.
The Declaration on Research Assessment (DORA): Opening up the measure of success.
We seem to have spent the last twenty years on the threshold of the open access “revolution". Though tremendous progress has been made, we have yet to realise all the potential that digital technology appeared to offer at the outset of the 21st Century. Part of the difficulty is that the scholarly community has become entangled by the metricisation of research assessment. Unpicking this knotty problem is the task that DORA – among others – has set itself. But it is not enough just to expose the problem. We have to focus on providing solutions that work for science and for society at large.
Maria Olivares (Head UZH Innovation, Zurich, CH)
Prajwal Prajwal (UZH Entrepreneurship Fellow, Co-Founder Clemedi, Institute of Laboratory Animal Science, Schlieren, CH)
Genetic Testing: Past, Present and Future
Most people think of the genome as static, but while your DNA doesn’t change, our knowledge about the relationship between your genetic variation and disease does. It was only in the 1990’s when the first genes for hereditary cancers were discovered and 2005 when the first genome-wide association study for common diseases bore fruit. Genetic testing really began taking off in 2013 and continues to expand as we unravel the genetic basis of disease. Big changes have occurred even in the last five years as we hone in on new genes, revise risk estimates associated with genetic variants and develop new applications, some of which are already being used in the clinic. In this presentation, you’ll learn about the state of the art in genetic testing: where we’ve been, where we’re at and where we're going.